Literature DB >> 21600817

The impact of pain in patients with polyneuropathy.

Ilia Poliakov1, Cory Toth.   

Abstract

Peripheral neuropathy (PN) is a common impairment which may impact upon quality of life (QoL). Neuropathic pain (NeP) occurs in up to 50% of patients with PN. We hypothesized that disability and impaired quality of life resulting from PN is primarily associated with presence of NeP. Our aim was to determine using prospectively identified PN patients presenting to a tertiary care neuromuscular clinic if presence of NeP (PN+NeP) had greater impact upon QoL than with absence of NeP (PN-NeP). A second aim was to identify if QoL varied based upon etiology of PN. We analyzed neuropathy severity (Toronto Clinical Neuropathy Score (TCSS)), pain quantity and quality (Visual Analogue Scale (VAS) pain score, Brief Pain Inventory (BPI)), QoL and health status measures (EuroQol Instrument 5 Domains (EQ-5D), Medical Outcomes Sleep Study Scale (MOSSS), Hospital Anxiety and Depression Scale (HADS), Short Form 36 Health Survey (SF-36)) and Health Assessment Questionnaire (HAQ) to determine impact of NeP. Although both cohorts were epidemiologically similar and had similar severity of PN, PN+NeP patients had considerably greater impairment for QoL, sleep efficacy, and features of anxiety and depression, leading to substantially greater health care resources utilization when compared to PN-NeP patients. The magnitude of NeP severity was the only explaining variable for increased impact upon QoL measures and diminishing overall wellbeing. Our results confirm that NeP is a primary indicator for worsening QoL and diminished overall wellbeing in PN patients. The etiology of PN did not influence levels of NeP-related compromise of QoL. Further studies are needed to determine optimal methods for management of PN+NeP patients subjected to a significant physiological, psychological and functional burden. Copyright Â
© 2011 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21600817     DOI: 10.1016/j.ejpain.2011.04.013

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  15 in total

1.  Chronic pain patients' treatment preferences: a discrete-choice experiment.

Authors:  Axel C Mühlbacher; Uwe Junker; Christin Juhnke; Edgar Stemmler; Thomas Kohlmann; Friedhelm Leverkus; Matthias Nübling
Journal:  Eur J Health Econ       Date:  2014-06-21

2.  The Global Burden of Polyneuropathy-In Need of an Accurate Assessment.

Authors:  Melissa A Elafros; Michelle P Kvalsund; Brian C Callaghan
Journal:  JAMA Neurol       Date:  2022-06-01       Impact factor: 29.907

3.  Enriched enrollment randomized double-blind placebo-controlled cross-over trial with phenytoin cream in painful chronic idiopathic axonal polyneuropathy (EPHENE): a study protocol.

Authors:  David J Kopsky; Ruben P A van Eijk; Janna K Warendorf; Jan M Keppel Hesselink; Nicolette C Notermans; Alexander F J E Vrancken
Journal:  Trials       Date:  2022-10-22       Impact factor: 2.728

4.  PEER systematic review of randomized controlled trials: Management of chronic neuropathic pain in primary care.

Authors:  Jamison Falk; Betsy Thomas; Jessica Kirkwood; Christina S Korownyk; Adrienne J Lindblad; Joey Ton; Samantha Moe; G Michael Allan; James McCormack; Scott Garrison; Nicolas Dugré; Karenn Chan; Michael R Kolber; Anthony Train; Liesbeth Froentjes; Logan Sept; Michael Wollin; Rodger Craig; Danielle Perry
Journal:  Can Fam Physician       Date:  2021-05       Impact factor: 3.275

Review 5.  World Health Organization essential medicines lists: where are the drugs to treat neuropathic pain?

Authors:  Peter R Kamerman; Antonia L Wadley; Karen D Davis; Aki Hietaharju; Parmanand Jain; Andreas Kopf; Ana-Claire Meyer; Srinivasa N Raja; Andrew S C Rice; Blair H Smith; Rolf-Detlef Treede; Philip J Wiffen
Journal:  Pain       Date:  2015-05       Impact factor: 7.926

6.  The importance of catastrophizing for successful pharmacological treatment of peripheral neuropathic pain.

Authors:  Cory Toth; Shauna Brady; Melinda Hatfield
Journal:  J Pain Res       Date:  2014-06-24       Impact factor: 3.133

7.  The analgesic effect of therapeutic rTMS is not mediated or predicted by comorbid psychiatric or sleep disorders.

Authors:  Pauliina Lindholm; Salla Lamusuo; Tero Taiminen; Arja Virtanen; Antti Pertovaara; Heli Forssell; Nora Hagelberg; Satu Jääskeläinen
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

8.  Neuropathic pain in the community: more under-treated than refractory?

Authors:  Nicola Torrance; Janice A Ferguson; Ebenezer Afolabi; Michael I Bennett; Michael G Serpell; Kate M Dunn; Blair H Smith
Journal:  Pain       Date:  2013-01-23       Impact factor: 7.926

Review 9.  Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects.

Authors:  Brigitte A Brouwer; Bianca T A de Greef; Janneke G J Hoeijmakers; Margot Geerts; Maarten van Kleef; Ingemar S J Merkies; Catharina G Faber
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

Review 10.  Understanding Monitoring Technologies for Adults With Pain: Systematic Literature Review.

Authors:  Iyubanit Rodríguez; Valeria Herskovic; Carmen Gerea; Carolina Fuentes; Pedro O Rossel; Maíra Marques; Mauricio Campos
Journal:  J Med Internet Res       Date:  2017-10-27       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.